Safety and Efficacy Study of rEV131 in Allergic Rhinitis

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Hay Fever

In brief

The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge. All patients enrolled will be known to be allergic to ragweed pollen and will be given ragweed pollen extract in both nostrils 30 minutes after either rEV131 or innactive vehicle (placebo). The signs and symptoms (sneezing, itching, stuffiness and runny nose) will each be given a score from 0 to 3 by the patient and these will be added together and the combined scores from patients treated with rEV131 will be compared with those who received placebo.

Key facts

Study ID

NCT00247520

Run by

Evolutec Group

People needed

112

Starts

2005-05-01

Expected to finish

2005-08-01

Last updated by the study team

2005-11-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• a) Have a known past history of allergic rhinitis including allergy to ragweed pollen.
• b) Able and willing to give informed consent. c) Able and willing to follow all study related instructions. d) Able and willing to make all required visits. e) Aged between 18 and 80 years. f) Willing to avoid prohibited medications (see below). g) Has met at least one of the endpoints to allergen challenge at Visit 1
• Total symptom score of at least 6 OR
• ≥ 30% reduction in nasal volume in at least one side of the nose as measured by acoustic rhinometry AND total symptom score of at least 4.
• h) Has met endpoint to allergen challenge at Visit 2: Total symptom score of at least 4 from a possible total of 12.

You may not qualify if…

• a) Patients with known exaggerated immuogenicity responses including severe asthma or peanut allergy.
• b) Patients with known allergy to ticks or severe reaction to arthropod venom (e.g. bee or wasp venom).
• c) Patients with known chronic sinusitis, deviated nasal septum or nasal polyposis.
• d) Patients having a total Baseline symptom score of >4 at Visit 1 (ie before the first nasal washout).
• e) Patients known or found to be allergic to pollens prevalent in the trial site locality during the period of the study (e.g. mountain cedar).
• f) Patients who have taken systemic or topical corticosteroids, long acting antihistamines or immunosuppressives within 4 weeks of selection (V1) or who take them within the course of the trial. Loratidine may not be taken within 10 days of entry. Short acting antihistamines may not be taken within 72 hours of entry except as comfort medication following nasal allergen challenge (oral antihistamines only). Patients excluded from the study for non-compliance with regard to prohibited medications but who have received one or more doses of the test medications will be included in the safety analysis.

Where it is running

• Diagnostics Research Group — San Antonio, Texas, United States
• Sylvana Research Associates — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.